Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and GIP , could represent a notable step forward for body management . Initial patient investigations have demonstrated considerable decreases in abdominal mass , conceivably exceeding existing weight-loss therapies . However , further evaluation is required to fully assess